This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

NICE guidance - referral criteria for familial breast cancer

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Guidance regarding referral of women with a history of familial breast cancer has been produced by NICE (1).

When considering referral decisions then attempts should be made to gather as accurate information as possible on:

  • age of diagnosis of any cancer in relatives
  • site of tumours
  • multiple cancers (including bilateral disease)
  • Jewish ancestry
  • Carrier probability at which genetic testing should be offered
    • When available in secondary care, use a carrier probability calculation method with demonstrated acceptable performance (in calibration and discrimination), as well as family history, to determine who should be offered referral to a specialist genetic clinic. Examples of acceptable methods include BOADICEA and the Manchester scoring system
      • offer genetic testing in specialist genetic clinics to a relative with a personal history of breast and/or ovarian cancer if that relative has a combined BRCA1 and BRCA2 mutation carrier probability of 10% or more
      • offer genetic testing in specialist genetic clinics to a person with no personal history of breast or ovarian cancer if their combined BRCA1 and BRCA2 mutation carrier probability is 10% or more and an affected relative is unavailable for testing

Near population risk

Moderate risk

High Risk *

Lifetime risk from age 20

Less than 17%

Greater than 17% but less than 30%

30% or greater

Risk between ages 40 and 50

Less than 3%

3-8%

Greater than 8%

*This group includes known BRCA1, BRCA2 and TP53 mutations and rare conditions that carry an increased risk of breast cancer such as Peutz-Jegher syndrome (STK11), Cowden (PTEN) and familial diffuse gastric cancer (E-Cadherin)

  • Surveillance for women with no personal history of breast cancer
    • Offer annual mammographic surveillance to women:
      • aged 40-49 years at moderate risk of breast cancer
      • aged 40-59 years at high risk of breast cancer but with a 30% or lower probability of being a BRCA or TP53 carrier
      • aged 40-59 years who have not had genetic testing but have a greater than 30% probability of being a BRCA carrier
      • aged 40-69 years with a known BRCA1 or BRCA2 mutation

    • Offer annual MRI surveillance to women:
      • aged 30-49 years who have not had genetic testing but have a greater than 30% probability of being a BRCA carrier
      • aged 30-49 years with a known BRCA1 or BRCA2 mutation
      • aged 20-49 years who have not had genetic testing but have a greater than 30% probability of being a TP53 carrier
      • aged 20-49 years with a known TP53 mutation

  • Surveillance for women with a personal and family history of breast cancer
    • offer annual mammographic surveillance to all women aged 50-69 years with a personal history of breast cancer who:
      • remain at high risk of breast cancer (including those who have a BRCA1 or BRCA2 mutation), and
      • do not have a TP53 mutation
    • offer annual MRI surveillance to all women aged 30-49 years with a personal history of breast cancer who remain at high risk of breast cancer, including those who have a BRCA1 or BRCA2 mutation

  • Chemoprevention for women with no personal history of breast cancer
    • offer either tamoxifen or raloxifene for 5 years to postmenopausal women with a uterus and at high risk of breast cancer unless they have a past history or may be at increased risk of thromboembolic disease or endometrial cancer

  • Risk-reducing mastectomy for women with no personal history of breast cancer
    • all women considering bilateral risk-reducing mastectomy should be able to discuss their breast reconstruction options (immediate and delayed) with a member of a surgical team with specialist oncoplastic or breast reconstructive skills

Women considered at 'near population risk' are managed in primary care.

The criteria defining when a women is 'near population risk' and appropriate for management in primary care are defined in the linked item below.

Reference:

  1. NICE guidance (June 2013). The classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care.

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.